drugset / Trial / NCT00577512
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
NaSingle-groupOpen-labelTreatment
Summary
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.
Timeline
- Start
- 2007-04
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 15 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 200 mg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 15 mg/m2 | — |
| Subject | Etoposide | Small molecule | 60 mg/m2 | — |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |